The Urokinase receptor, also known as uPA receptor or uPAR or CD87 (Cluster of Differentiation 87), is multidomain glycoprotein tethered to the cell membrane with a glycosylphosphotidylinositol (GPI) anchor. uPAR plays a central role in cell surface-associated plasminogen activation, entailing proteolytic degradation of the extracellular matrix surrounding the cells. The prognostic significance of uPAR in non-small cell lung cancer is apparent for patients with the histologic subtype of squamous cell carcinoma, where high levels of uPAR is an independent marker of prognosis, as evaluated in tumour extracts. Like in non-small cell lung cancer, uPAR domain I present in high concentrations in preoperative plasma independently predicts poor survival of patients with ovarian cancer.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Receptor Construction||Vector Type||Targeting Cell Type||Inquiry & Datasheet|
|CAR-LC265||Anti-CD87 h(41BB-CD3ζ) CAR, pCDCAR1||Human||Human||scFv-41BB-CD3ζ-IL12||Lentiviral||T cell|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases||Inquiry & Datasheet|
|VP-CAR-LC734||Lenti-CD87 CAR (scFv-41BB-CD3ζ-IL12) Viral Particle||EF1a||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE